Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How has the short-acting b2 agonists market size changed in recent years, and what is the outlook ahead?
The short-acting B2 agonist market size has grown steadily in recent years. It will grow from $4.25 billion in 2024 to $4.44 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to growth in the pediatric asthma population, increasing prevalence of environmental allergens, rising urbanization and pollution levels, rising focus on the prevention of asthma exacerbations, and growing number of research and development initiatives.
The short-acting B2 agonist market size is expected to see steady growth in the next few years. It will grow to $5.29 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to rising prevalence of asthma and chronic obstructive pulmonary disease, increasing awareness about asthma management, increasing government initiatives for asthma and copd treatment, rising healthcare expenditure globally, and expanding geriatric population. Major trends in the forecast period include advancements in inhaler technologies, expanding market for personalized asthma treatments, convenient drug delivery systems, technological advancements in nebulizers for home use, and improvements in drug formulation for better efficacy.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24396&type=smp
What are the top economic and technological drivers pushing short-acting b2 agonists market growth?
The increasing prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the short-acting B2 agonists market going forward. Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that causes breathing difficulties and reduced airflow, mainly due to prolonged exposure to harmful gases or cigarette smoke. The rise in chronic obstructive pulmonary disease (COPD) is due to increasing exposure to air pollution, as long-term inhalation of pollutants like particulate matter and toxic gases can harm lung tissue and accelerate the disease’s development. Short-acting ß2-agonists (SABAs) are used in COPD to quickly relieve symptoms like shortness of breath by relaxing airway muscles. They act as rescue medications during flare-ups but are not meant for long-term control. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022, chronic obstructive pulmonary disease (COPD) accounted for 7,691 deaths, or 29.6 per 100,000 population, representing 4.0% of all fatalities. Therefore, the increasing prevalence of chronic obstructive pulmonary disease will boost the growth of the short-acting B2 agonists market.
How is the short-acting b2 agonists market segmented by product, application, and end-user?
The short-acting B2 agonists market covered in this report is segmented –
1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types
2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
3) By Administration Route: Inhalation, Oral, Injection
4) By End User: Hospitals, Clinics, Home Healthcare Settings
Subsegments:
1) By Albuterol: Inhalers, Nebulizers, Tablets, Syrups
2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions
3) By Metaproterenol: Inhalers, Syrups
4) By Other Types: Terbutaline, Pirbuterol, Salbutamol
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/short-acting-b2-agonists-global-market-report
What technological trends are expected to redefine the short-acting b2 agonists market?
Major companies in the short-acting B2 agonists market are focusing on developing technologically advanced products, such as pressurized metered-dose inhalers (pMDI), to help manage acute symptoms efficiently. Pressurized metered-dose inhalers (pMDIs) are handheld devices that deliver a specific dose of medication to the lungs in aerosol form using a propellant-driven spray commonly used for treating respiratory conditions like asthma and COPD. For instance, in January 2023, AstraZeneca, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval for Airsupra (albuterol/budesonide). Airsupra is a first-in-class pressurized metered-dose inhaler (pMDI) that combines two active ingredients in a fixed-dose formulation. It contains albuterol, a short-acting beta2-agonist (SABA), for rapid bronchodilation, and budesonide, an inhaled corticosteroid (ICS), to reduce inflammation. This unique combination is approved in the US for the as-needed treatment and prevention of bronchoconstriction in adults with asthma. Additionally, it helps reduce the risk of exacerbations, providing a comprehensive approach to asthma management.
Which leading companies are dominating the short-acting b2 agonists market landscape?
Major companies operating in the short-acting B2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.
Which geographic areas are expected to offer the highest growth opportunities in theshort-acting b2 agonists market?
North America was the largest region in the short-acting B2 agonists market in 2024. The regions covered in the short-acting B2 agonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Short-Acting B2 Agonists Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24396&type=smp
Need Customized Data On Short-Acting B2 Agonists Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24396&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
